Company intelligence / Profile preview
NB Health Laboratory
Sapporo, Hokkaido, Japannbhl.co.jp ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Preclinical
01
Overview
The company has multiple preclinical programs targeting various indications, with a focus on GPCR-targeted antibodies. Their most advanced programs include NBA-1901, P-007, NBG-029, NBG-025, and NBA-1603, all in preclinical stage.
- Therapeutic areas
- PulmonologyRheumatologyImmunologyOtherNeurology
- Modalities
- Monoclonal antibodiesAntibodies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on NB Health Laboratory.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB Health Laboratory.